Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 427

1.

Association of Amyloid and Tau With Cognition in Preclinical Alzheimer Disease: A Longitudinal Study.

Hanseeuw BJ, Betensky RA, Jacobs HIL, Schultz AP, Sepulcre J, Becker JA, Cosio DMO, Farrell M, Quiroz YT, Mormino EC, Buckley RF, Papp KV, Amariglio RA, Dewachter I, Ivanoiu A, Huijbers W, Hedden T, Marshall GA, Chhatwal JP, Rentz DM, Sperling RA, Johnson K.

JAMA Neurol. 2019 Jun 3. doi: 10.1001/jamaneurol.2019.1424. [Epub ahead of print]

PMID:
31157827
2.

Sustained Long-Term Efficacy and Safety of Adalimumab in Pediatric Patients with Severe Chronic Plaque Psoriasis from a Randomised, Double-Blind, Phase 3 Study.

Thaçi D, Papp K, Marcoux D, Weibel L, Pinter A, Ghislain PD, Landells I, Hoeger PH, Unnebrink K, Seyger MMB, Williams DA, Rubant S, Philipp S.

Br J Dermatol. 2019 Apr 24. doi: 10.1111/bjd.18029. [Epub ahead of print]

PMID:
31017657
3.

Patient safety culture in Hungarian hospitals.

Granel N, Manresa-Domínguez JM, Barth A, Papp K, Bernabeu-Tamayo MD.

Int J Health Care Qual Assur. 2019 Mar 11;32(2):412-424. doi: 10.1108/IJHCQA-02-2018-0048.

PMID:
31017066
4.

Tackling Some Wicked Problems in Medical Education.

Denton GD, Papp KK.

J Gen Intern Med. 2019 May;34(5):652-653. doi: 10.1007/s11606-019-04930-x. No abstract available.

PMID:
30993613
5.

Assessment of the effects of immunogenicity on the pharmacokinetics, efficacy and safety of tildrakizumab.

Kimball AB, Kerbusch T, van Aarle F, Kulkarni P, Li Q, Blauvelt A, Papp KA, Reich K, Montgomery D.

Br J Dermatol. 2019 Mar 27. doi: 10.1111/bjd.17918. [Epub ahead of print]

PMID:
30916381
6.

Assessing the Synergistic Effect of a Fixed Combination Halobetasol Propionate 0.01% and Tazarotene 0.045% Lotion in Moderate-to-Severe Plaque Psoriasis

Kircik LH, Papp KA, Stein Gold L, Harris S, Pharm TL, Pillai R.

J Drugs Dermatol. 2019 Mar 1;18(3):279-284..

PMID:
30909333
7.

Demography, baseline disease characteristics, and treatment history of psoriasis patients with self-reported psoriatic arthritis enrolled in the PSOLAR registry.

Kavanaugh A, Papp K, Gottlieb AB, de Jong EMGJ, Chakravarty SD, Kafka S, Langholff W, Farahi K, Srivastava B, Scher JU.

BMC Rheumatol. 2018 Sep 29;2:29. doi: 10.1186/s41927-018-0034-7. eCollection 2018.

8.

An UNC5C Allele Predicts Cognitive Decline and Hippocampal Atrophy in Clinically Normal Older Adults.

Yang HS, Chhatwal JP, Xu J, White CC, Hanseeuw B, Rabin JS, Papp KV, Buckley RF, Schultz AP, Properzi MJ, Gatchel JR, Amariglio RE, Donovan NJ, Mormino EC, Hedden T, Marshall GA, Rentz DM, Johnson KA, De Jager PL, Sperling RA.

J Alzheimers Dis. 2019;68(3):1161-1170. doi: 10.3233/JAD-180788.

9.

Efficacy of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials at weeks 12 and 28.

Papp KA, Reich K, Blauvelt A, Kimball AB, Gooderham M, Tyring SK, Sinclair R, Thaci D, Li Q, Cichanowitz N, Green S, La Rosa C.

J Eur Acad Dermatol Venereol. 2019 Jun;33(6):1098-1106. doi: 10.1111/jdv.15400. Epub 2019 Mar 5.

PMID:
30838709
10.

Treating to Target(s) With Interleukin-17 Inhibitors.

Lynde CW, Beecker J, Dutz J, Flanagan C, Guenther LC, Gulliver W, Papp K, Rahman P, Sholter D, Searles GE.

J Cutan Med Surg. 2019 Mar/Apr;23(2_suppl):3S-34S. doi: 10.1177/1203475418824565. Epub 2019 Feb 11.

PMID:
30742778
11.

Efficacy and safety of mirikizumab (LY3074828) in the treatment of moderate-to-severe plaque psoriasis: results from a randomized phase II study.

Reich K, Rich P, Maari C, Bissonnette R, Leonardi C, Menter A, Igarashi A, Klekotka P, Patel D, Li J, Tuttle J, Morgan-Cox M, Edson-Heredia E, Friedrich S, Papp K; AMAF investigators.

Br J Dermatol. 2019 Feb 7. doi: 10.1111/bjd.17628. [Epub ahead of print]

PMID:
30734266
12.

Sex Differences in the Association of Global Amyloid and Regional Tau Deposition Measured By Positron Emission Tomography in Clinically Normal Older Adults.

Buckley RF, Mormino EC, Rabin JS, Hohman TJ, Landau S, Hanseeuw BJ, Jacobs HIL, Papp KV, Amariglio RE, Properzi MJ, Schultz AP, Kirn D, Scott MR, Hedden T, Farrell M, Price J, Chhatwal J, Rentz DM, Villemagne VL, Johnson KA, Sperling RA.

JAMA Neurol. 2019 Feb 4. doi: 10.1001/jamaneurol.2018.4693. [Epub ahead of print]

PMID:
30715078
13.

Vaccination Guidelines for Patients with Immune-mediated Disorders Taking Immunosuppressive Therapies: Executive Summary.

Papp KA, Haraoui B, Kumar D, Marshall JK, Bissonnette R, Bitton A, Bressler B, Gooderham M, Ho V, Jamal S, Pope JE, Steinhart AH, Vinh DC, Wade J.

J Rheumatol. 2019 Feb 1. pii: jrheum.180784. doi: 10.3899/jrheum.180784. [Epub ahead of print]

14.

Regional Tau Correlates of Instrumental Activities of Daily Living and Apathy in Mild Cognitive Impairment and Alzheimer's Disease Dementia.

Marshall GA, Gatchel JR, Donovan NJ, Muniz MC, Schultz AP, Becker JA, Chhatwal JP, Hanseeuw BJ, Papp KV, Amariglio RE, Rentz DM, Sperling RA, Johnson KA.

J Alzheimers Dis. 2019;67(2):757-768. doi: 10.3233/JAD-170578.

15.

The impact of amyloid-beta and tau on prospective cognitive decline in older individuals.

Sperling RA, Mormino EC, Schultz AP, Betensky RA, Papp KV, Amariglio RE, Hanseeuw BJ, Buckley R, Chhatwal J, Hedden T, Marshall GA, Quiroz YT, Donovan NJ, Jackson J, Gatchel JR, Rabin JS, Jacobs H, Yang HS, Properzi M, Kirn DR, Rentz DM, Johnson KA.

Ann Neurol. 2019 Feb;85(2):181-193. doi: 10.1002/ana.25395. Epub 2019 Jan 21.

PMID:
30549303
16.

Safety of guselkumab in patients with moderate-to-severe psoriasis treated through 100 weeks: a pooled analysis from the randomized VOYAGE 1 and VOYAGE 2 studies.

Reich K, Papp KA, Armstrong AW, Wasfi Y, Li S, Shen YK, Randazzo B, Song M, Kimball AB.

Br J Dermatol. 2019 May;180(5):1039-1049. doi: 10.1111/bjd.17454.

PMID:
30485400
17.

Tau Accumulation in Clinically Normal Older Adults Is Associated with Hippocampal Hyperactivity.

Huijbers W, Schultz AP, Papp KV, LaPoint MR, Hanseeuw B, Chhatwal JP, Hedden T, Johnson KA, Sperling RA.

J Neurosci. 2019 Jan 16;39(3):548-556. doi: 10.1523/JNEUROSCI.1397-18.2018. Epub 2018 Nov 27.

PMID:
30482786
18.

Vaccination Guidelines for Patients With Immune-Mediated Disorders on Immunosuppressive Therapies.

Papp KA, Haraoui B, Kumar D, Marshall JK, Bissonnette R, Bitton A, Bressler B, Gooderham M, Ho V, Jamal S, Pope JE, Steinhart AH, Vinh DC, Wade J.

J Cutan Med Surg. 2019 Jan/Feb;23(1):50-74. doi: 10.1177/1203475418811335. Epub 2018 Nov 21.

19.

Approach to the Assessment and Management of Adult Patients With Atopic Dermatitis: A Consensus Document. Section V: Consensus Statements on the Assessment and Management of Adult Patients With Moderate-to-Severe Atopic Dermatitis.

Hong CH, Gooderham MJ, Albrecht L, Bissonnette R, Dhadwal G, Gniadecki R, Grewal P, Kirchhof MG, Landells I, Lansang P, Lynde CW, Papp KA, Poulin Y, Sussman G, Turchin I, Wiseman M, Yeung J.

J Cutan Med Surg. 2018 Nov/Dec;22(1_suppl):30S-35S. doi: 10.1177/1203475418803625.

PMID:
30439300
20.

Approach to the Assessment and Management of Adult Patients With Atopic Dermatitis: A Consensus Document.

Gooderham MJ, Hong CH, Albrecht L, Bissonnette R, Dhadwal G, Gniadecki R, Grewal P, Kirchhof MG, Landells I, Lansang P, Lynde CW, Papp KA, Poulin Y, Sussman G, Turchin I, Wiseman M, Yeung J.

J Cutan Med Surg. 2018 Nov/Dec;22(1_suppl):3S-5S. doi: 10.1177/1203475418803627.

PMID:
30439298
21.

Approach to the Assessment and Management of Adult Patients With Atopic Dermatitis: A Consensus Document. Section II: Tools for Assessing the Severity of Atopic Dermatitis.

Gooderham MJ, Bissonnette R, Grewal P, Lansang P, Papp KA, Hong CH.

J Cutan Med Surg. 2018 Nov/Dec;22(1_suppl):10S-16S. doi: 10.1177/1203475418803628.

PMID:
30439297
22.
23.

Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 Studies.

Nash P, Coates LC, Fleischmann R, Papp KA, Gomez-Reino JJ, Kanik KS, Wang C, Wu J, Menon S, Hendrikx T, Ports WC.

Rheumatol Ther. 2018 Dec;5(2):567-582. doi: 10.1007/s40744-018-0131-5. Epub 2018 Nov 9.

24.

Antibiotic-resistant Escherichia coli from retail poultry meat with different antibiotic use claims.

Davis GS, Waits K, Nordstrom L, Grande H, Weaver B, Papp K, Horwinski J, Koch B, Hungate BA, Liu CM, Price LB.

BMC Microbiol. 2018 Nov 3;18(1):174. doi: 10.1186/s12866-018-1322-5.

25.

Solitary Trochleoplasty for Treatment of Recurrent Patellar Dislocation.

Camathias C, Speth BM, Rutz E, Schlemmer T, Papp K, Vavken P, Studer K.

JBJS Essent Surg Tech. 2018 Apr 11;8(2):e11. doi: 10.2106/JBJS.ST.17.00039. eCollection 2018 Jun 27.

26.

The topoisomerase 3α zinc-finger domain T1 of Arabidopsis thaliana is required for targeting the enzyme activity to Holliday junction-like DNA repair intermediates.

Dorn A, Röhrig S, Papp K, Schröpfer S, Hartung F, Knoll A, Puchta H.

PLoS Genet. 2018 Sep 17;14(9):e1007674. doi: 10.1371/journal.pgen.1007674. eCollection 2018 Sep.

27.

Efficacy and safety of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults: A pooled analysis of two phase 2 clinical trials.

Tofte SJ, Papp K, Sadick N, Bohnert K, Simpson E, Thaçi D, Bieber T, Blauvelt A, Sofen H, Gooderham M, Chen Z, Gadkari A, Eckert L, Graham NMH, Pirozzi G, Ardeleanu M.

J Am Assoc Nurse Pract. 2018 Sep;30(9):529-541. doi: 10.1097/JXX.0000000000000088.

PMID:
30211823
28.

Granulocyte-macrophage colony-stimulating factor (GM-CSF) as a therapeutic target in psoriasis: randomized, controlled investigation using namilumab, a specific human anti-GM-CSF monoclonal antibody.

Papp KA, Gooderham M, Jenkins R, Vender R, Szepietowski JC, Wagner T, Hunt B, Souberbielle B; NEPTUNE investigators.

Br J Dermatol. 2019 Jun;180(6):1352-1360. doi: 10.1111/bjd.17195. Epub 2018 Nov 2.

PMID:
30207587
29.

Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis.

Papp K, Gordon K, Thaçi D, Morita A, Gooderham M, Foley P, Girgis IG, Kundu S, Banerjee S.

N Engl J Med. 2018 Oct 4;379(14):1313-1321. doi: 10.1056/NEJMoa1806382. Epub 2018 Sep 11.

30.

Comprehensive long-term safety of adalimumab from 18 clinical trials in adult patients with moderate-to-severe plaque psoriasis.

Leonardi C, Papp K, Strober B, Thaçi D, Warren RB, Tyring S, Arikan D, Karunaratne M, Valdecantos WC.

Br J Dermatol. 2019 Jan;180(1):76-85. doi: 10.1111/bjd.17084. Epub 2018 Oct 10.

PMID:
30169904
31.

Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two Years.

Griffiths CEM, Papp KA, Kimball AB, Randazzo B, Song M, Li S, Shen YK, Blauvelt A.

J Drugs Dermatol. 2018 Aug 1;17(8):826-832.

PMID:
30124721
32.

Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.

Gordon KB, Strober B, Lebwohl M, Augustin M, Blauvelt A, Poulin Y, Papp KA, Sofen H, Puig L, Foley P, Ohtsuki M, Flack M, Geng Z, Gu Y, Valdes JM, Thompson EHZ, Bachelez H.

Lancet. 2018 Aug 25;392(10148):650-661. doi: 10.1016/S0140-6736(18)31713-6. Epub 2018 Aug 7.

PMID:
30097359
33.

Quantitative stable isotope probing with H218O reveals that most bacterial taxa in soil synthesize new ribosomal RNA.

Papp K, Mau RL, Hayer M, Koch BJ, Hungate BA, Schwartz E.

ISME J. 2018 Dec;12(12):3043-3045. doi: 10.1038/s41396-018-0233-7. Epub 2018 Jul 24.

PMID:
30042501
34.

A Three-Factor Structure of Cognitive Functioning Among Unimpaired Carriers and Non-Carriers of Autosomal-Dominant Alzheimer's Disease.

Guzmán-Vélez E, Jaimes S, Aguirre-Acevedo DC, Norton DJ, Papp KV, Amariglio R, Rentz D, Baena A, Henao E, Tirado V, Muñoz C, Giraldo M, Sperling RA, Lopera F, Quiroz YT.

J Alzheimers Dis. 2018;65(1):107-115. doi: 10.3233/JAD-180078.

PMID:
30040714
35.

The Impact of Awareness of and Concern About Memory Performance on the Prediction of Progression From Mild Cognitive Impairment to Alzheimer Disease Dementia.

Munro CE, Donovan NJ, Amariglio RE, Papp KV, Marshall GA, Rentz DM, Pascual-Leone A, Sperling RA, Locascio JJ, Vannini P.

Am J Geriatr Psychiatry. 2018 Aug;26(8):896-904. doi: 10.1016/j.jagp.2018.04.008. Epub 2018 May 3.

PMID:
29866588
36.

Sex, amyloid, and APOE ε4 and risk of cognitive decline in preclinical Alzheimer's disease: Findings from three well-characterized cohorts.

Buckley RF, Mormino EC, Amariglio RE, Properzi MJ, Rabin JS, Lim YY, Papp KV, Jacobs HIL, Burnham S, Hanseeuw BJ, Doré V, Dobson A, Masters CL, Waller M, Rowe CC, Maruff P, Donohue MC, Rentz DM, Kirn D, Hedden T, Chhatwal J, Schultz AP, Johnson KA, Villemagne VL, Sperling RA; Alzheimer's Disease Neuroimaging Initiative; Australian Imaging, Biomarker and Lifestyle study of ageing; Harvard Aging Brain Study.

Alzheimers Dement. 2018 Sep;14(9):1193-1203. doi: 10.1016/j.jalz.2018.04.010. Epub 2018 May 24.

PMID:
29803541
37.

Interactive Associations of Vascular Risk and β-Amyloid Burden With Cognitive Decline in Clinically Normal Elderly Individuals: Findings From the Harvard Aging Brain Study.

Rabin JS, Schultz AP, Hedden T, Viswanathan A, Marshall GA, Kilpatrick E, Klein H, Buckley RF, Yang HS, Properzi M, Rao V, Kirn DR, Papp KV, Rentz DM, Johnson KA, Sperling RA, Chhatwal JP.

JAMA Neurol. 2018 Sep 1;75(9):1124-1131. doi: 10.1001/jamaneurol.2018.1123.

38.

PET staging of amyloidosis using striatum.

Hanseeuw BJ, Betensky RA, Mormino EC, Schultz AP, Sepulcre J, Becker JA, Jacobs HIL, Buckley RF, LaPoint MR, Vannini P, Donovan NJ, Chhatwal JP, Marshall GA, Papp KV, Amariglio RE, Rentz DM, Sperling RA, Johnson KA; Alzheimer's Disease Neuroimaging Initiative; Harvard Aging Brain Study.

Alzheimers Dement. 2018 Oct;14(10):1281-1292. doi: 10.1016/j.jalz.2018.04.011. Epub 2018 May 21.

39.
40.

The relationship between recall of recently versus remotely encoded famous faces and amyloidosis in clinically normal older adults.

Orlovsky I, Huijbers W, Hanseeuw BJ, Mormino EC, Hedden T, Buckley RF, LaPoint M, Rabin JS, Rentz DM, Johnson KA, Sperling RA, Papp KV.

Alzheimers Dement (Amst). 2017 Nov 23;10:121-129. doi: 10.1016/j.dadm.2017.11.003. eCollection 2018.

41.

Safety of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials.

Blauvelt A, Reich K, Papp KA, Kimball AB, Gooderham M, Tyring SK, Sinclair R, Thaçi D, Li Q, Cichanowitz N, Green S, La Rosa C.

Br J Dermatol. 2018 Sep;179(3):615-622. doi: 10.1111/bjd.16724. Epub 2018 Jul 4.

PMID:
29742274
42.

Randomized, controlled study of bleselumab (ASKP1240) pharmacokinetics and safety in patients with moderate-to-severe plaque psoriasis.

Anil Kumar MS, Papp K, Tainaka R, Valluri U, Wang X, Zhu T, Schwabe C.

Biopharm Drug Dispos. 2018 May;39(5):245-255. doi: 10.1002/bdd.2130.

43.

Response to 'Psoriasis patients' preference for an aerosol foam topical formulation' by Vender R et al.

Hong CH, Papp KA, Lophaven KW, Skallerup P, Philipp S.

J Eur Acad Dermatol Venereol. 2018 Nov;32(11):e401-e402. doi: 10.1111/jdv.14985. Epub 2018 May 7. No abstract available.

PMID:
29633353
44.

Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial.

Papp KA, Merola JF, Gottlieb AB, Griffiths CEM, Cross N, Peterson L, Cioffi C, Blauvelt A.

J Am Acad Dermatol. 2018 Aug;79(2):277-286.e10. doi: 10.1016/j.jaad.2018.03.037. Epub 2018 Mar 30.

45.

Correction to: Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3).

Blauvelt A, Papp KA, Griffiths CEM, Puig L, Weisman J, Dutronc Y, Kerr LF, Ilo D, Mallbris L, Augustin M.

Am J Clin Dermatol. 2018 Jun;19(3):457. doi: 10.1007/s40257-018-0353-x.

46.

Brodalumab: A Review of Safety.

Rusta-Sallehy S, Gooderham M, Papp K.

Skin Therapy Lett. 2018 Mar;23(2):1-3. Review.

47.

Effect of psoriatic arthritis on ixekizumab clinical outcomes in moderate-to-severe psoriasis patients: A post hoc analysis.

Gottlieb AB, Papp KA, Birbara CA, Shuler CL, Burge R, Erickson J, Kerr L, Mease PJ.

J Am Acad Dermatol. 2018 Sep;79(3):593-595. doi: 10.1016/j.jaad.2018.03.008. Epub 2018 Mar 17. No abstract available.

PMID:
29559395
48.

Onset of Action of Biologics in Patients With Moderate-to-Severe Psoriasis.

Papp KA, Lebwohl MG.

J Drugs Dermatol. 2017 Mar 1;17(3):247-250. Review.

PMID:
29537442
49.

Patient-reported symptoms and signs of moderate-to-severe psoriasis treated with guselkumab or adalimumab: results from the randomized VOYAGE 1 trial.

Papp KA, Blauvelt A, Kimball AB, Han C, Randazzo B, Wasfi Y, Shen YK, Li S, Griffiths CEM.

J Eur Acad Dermatol Venereol. 2018 Sep;32(9):1515-1522. doi: 10.1111/jdv.14910. Epub 2018 Apr 10.

50.

Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3.

Papp KA, Gordon KB, Langley RG, Lebwohl MG, Gottlieb AB, Rastogi S, Pillai R, Israel RJ.

Br J Dermatol. 2018 Aug;179(2):320-328. doi: 10.1111/bjd.16464. Epub 2018 May 23.

PMID:
29488226

Supplemental Content

Support Center